| Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma JA Rader, MR Russell, LS Hart, MS Nakazawa, LT Belcastro, D Martinez, ... Clinical cancer research 19 (22), 6173-6182, 2013 | 408 | 2013 |
| RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma KA Cole, J Huggins, M Laquaglia, CE Hulderman, MR Russell, K Bosse, ... Proceedings of the National Academy of Sciences 108 (8), 3336-3341, 2011 | 281 | 2011 |
| CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus MR Russell, A Penikis, DA Oldridge, JR Alvarez-Dominguez, L McDaniel, ... Cancer research 75 (15), 3155-3166, 2015 | 156 | 2015 |
| Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma MR Russell, K Levin, JA Rader, L Belcastro, Y Li, D Martinez, B Pawel, ... Cancer research 73 (2), 776-784, 2013 | 144 | 2013 |
| Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features Q Liu, MR Russell, K Shahriari, DL Jernigan, MI Lioni, FU Garcia, ... Cancer research 73 (11), 3297-3305, 2013 | 128 | 2013 |
| Rare Variants in TP53 and Susceptibility to Neuroblastoma SJ Diskin, M Capasso, M Diamond, DA Oldridge, K Conkrite, KR Bosse, ... Journal of the National Cancer Institute 106 (4), dju047, 2014 | 123 | 2014 |
| Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma LS Hart, JA Rader, P Raman, V Batra, MR Russell, M Tsang, M Gagliardi, ... Clinical Cancer Research 23 (7), 1785-1796, 2017 | 81 | 2017 |
| Targeting the α receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis MR Russell, Q Liu, A Fatatis Clinical Cancer Research 16 (20), 5002-5010, 2010 | 55 | 2010 |
| Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the α-Platelet–Derived Growth Factor Receptor NG Dolloff, MR Russell, N Loizos, A Fatatis Cancer research 67 (2), 555-562, 2007 | 55 | 2007 |
| The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma M Capasso, LD McDaniel, F Cimmino, A Cirino, D Formicola, MR Russell, ... Journal of Cellular and Molecular Medicine 21 (12), 3224-3230, 2017 | 51 | 2017 |
| The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells MR Russell, WL Jamieson, NG Dolloff, A Fatatis Oncogene 28 (3), 412-421, 2009 | 47 | 2009 |
| The α-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand-and dimerization-independent mechanisms MR Russell, Q Liu, H Lei, A Kazlauskas, A Fatatis Cancer research 70 (10), 4195-4203, 2010 | 26 | 2010 |
| Microenvironment Factors Influencing Skeletal Metastases A Fatatis, JA D'Ambrosio, WL Jamieson, DL Jernigan, MR Russell Tumor Microenvironment, 135-160, 2010 | | 2010 |
| Antagonism of platelet-derived growth factor receptor-α as a potential therapeutic for prostate cancer bone metastases MR Russell, Q Liu, H Lei, A Kazlauskas, A Fatatis Cancer Research 70 (8_Supplement), 1468-1468, 2010 | | 2010 |
John M MarisProfessor Pediatrics, Children's Hospital of Philadelphia and University of PennsylvaniaVerified email at chop.edu
